![Henning R. Stennicke](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Henning R.
Stennicke is currently the Chief Scientific Officer at Freeline Therapeutics Holdings Plc since 2022.
Prior to this, he worked as the Project Vice President-Global Development Biopharm at Novo Nordisk A. He holds an MBA from the Technical University of Denmark and a graduate degree from the University of Copenhagen.
| Sociétés | Poste | Début |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Directeur Technique/Scientifique/R&D | 01/03/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Technical University of Denmark
 Technical University of Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
